

## KIDNEY STONES

112. Lemann J Jr, Litzow R, Lennon EJ: The effects of chronic acid loads in normal man: Further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis. *J Clin Invest* 45:1608-1614, Oct 1966
113. Coe FL, Firpo JJ Jr: Evidence for mild reversible hyperparathyroidism in distal renal tubular acidosis. *Arch Intern Med* 135:1485-1489, Nov 1975
114. Lemann J Jr, Litzow JR, Lennon EJ: Studies of the mechanism by which chronic metabolic acidosis augments urinary calcium excretion in man. *J Clin Invest* 46:1318-1328, Aug 1967
115. Sutton RA, Wong NLM, Dirks JH: The hypercalciuria of metabolic acidosis: A specific impairment of distal calcium reabsorption. *Clin Res* 23:434A, Apr 1975
116. Nash MA, Torrado AD, Greifer I, et al: Renal tubular acidosis in infants and children—Clinical course, response to treatment, and prognosis. *J Pediatr* 80:738-748, May 1972
117. Cohen JJ, Kamm DE: Renal metabolism: Relation to renal function. In Brenner BM, Rector FC Jr (Eds): *The Kidney—Vol 1, Section 1*, Philadelphia, Pa, Saunders Co, 1976, pp 126-214
118. Morrissey JF, Ochoa M Jr, Lotspeich WD, et al: Citrate excretion in renal tubular acidosis. *Ann Intern Med* 58:159-166, Jan 1963
119. Thier SO, Segal S: Cystinuria. In Stanbury JB, Wyngaarden JB, Fredrickson DS (Eds): *The Metabolic Basis of Inherited Disease*. New York, McGraw-Hill Book Co., 1978, pp 1578-1592
120. Dent CE, Senior B: Studies on the treatment of cystinuria. *Br J Urol* 27:317-332, Dec 1955
121. Dent CE, Friedman M, Green H, et al: Treatment of cystinuria. *Br Med J* 1:403-408, Feb 1965
122. Crawhall JC, Watts RW: Cystinuria. *Am J Med* 45:736-755, Nov 1968
123. Dagaard OZ: Polycystic disease of the kidneys. In Strauss MB, Welt LG (Ed): *Diseases of the Kidney*, 2nd Ed. Boston, Little, Brown and Co, 1971, pp 1223-1258
124. Gill G, Pallotta J, Kashgarian M, et al: Physiologic studies in renal osteodystrophy treated by subtotal parathyroidectomy. *Am J Med* 46:930-940, Jun 1969
125. Meschan I: *Roentgen Signs in Clinical Practice*, 2 vols. Philadelphia, WB Saunders Co, 1966
126. Ekström T, Engfeldt B, Lagergren C, et al: Medullary Sponge Kidney. Stockholm, Almqvist and Wiksell, 1959
127. Thomas WC Jr: *Renal Calculi—A Guide to Management*. Springfield, IL Charles C Thomas, 1976
128. Libertino JA, Newman HR, Lytton B, et al: Staghorn calculi in solitary kidneys. *J Urol* 105:753-757, Jun 1971
129. Blandy JP, Singh M: The case for a more aggressive approach to staghorn stones. *J Urol* 115:505-506, May 1976
130. Swanson DA, Sullivan MJ, Palmer JM: Branched renal calculi. *West J Med* 125:354-360, Nov 1976
131. Gil-Vernet J: New surgical concepts in removing renal calculi. *Urol Int* 20:255-288, 1965
132. Smith MJ, Boyce WH: Anatomic nephrectomy and plastic calyrrhaphy. *Trans Am Assoc Genitourin Surg* 59:18-24, 1967
133. Harrison LH, Nordan JM: Symposium on renal lithiasis. Anatomic nephrectomy for removal of renal calculi. *Urol Clin North Am* 1:333-344, Jun 1974
134. Stephenson TP, Bauer S, Hargreave TB, et al: The technique and results of pyelocalycotomy for staghorn calculi. *Br J Urol* 47:751-758, 1976
135. Marshall VR, Singh M, Tresidder GC, et al: The place of partial nephrectomy in the management of renal calyceal calculi. *Br J Urol* 47:759-764, 1976
136. Boyce WH (guest editor): Symposium on renal lithiasis. *Urol Clin North Am* 1:179-383, Jun 1974
137. Boxer RJ, Johnson SF, Ehrlich RM: Ureteral substitution. *Urology* 12:269-278, Sep 1978
138. Skinner DG, Goodwin WE: Indications for the use of intestinal segments in management of nephrocalcinosis. *Trans Am Assoc Genitourin Surg* 66:158-169, 1974
139. Dees JE: The use of fibrinogen coagulum in pyelolithotomy. *J Urol* 56:271-283, Sep 1946
140. Patel VJ: The coagulum pyelolithotomy. *Br J Surg* 60:230-236, Mar 1973
141. Rathore A, Harrison JH: Coagulum pyelolithotomy using autogenous plasma and bovine thrombin. *J Urol* 116:8-10, Jul 1976
142. Seddon JM, Bonin RE: Coagulum pyelolithotomy. *Urology* 9:564-565, May 1977
143. Nemoy NJ, Stamey TA: Surgical, bacteriological, and biochemical management of "infection stones." *JAMA* 215:1470-1476, Mar 1971
144. Nemoy NJ, Stamey TA: Use of hemiacidrin in management of infection stones. *J Urol* 116:693-695, Dec 1976
145. Fam B, Rossier AB, Yalla S, et al: The role of hemiacidrin in the management of renal stones in spinal cord injury patients. *J Urol* 116:696-698, Dec 1976

## Myasthenia Secondary to Penicillamine

MYASTHENIA HAS BEEN FOUND to be a complication of penicillamine, a drug being used increasingly in the treatment of rheumatoid arthritis. . . . After years of speculation about a possible chemical abnormality as the cause of myasthenia, recent work has pinpointed the defect to a decreased number of available acetylcholine receptors in muscle. The decrease in the number of available receptors is due to the binding of many of these receptors by antiacetylcholine receptor antibodies. . . . Since penicillamine is known to produce some of its complications by means of antibody induction, and since myasthenia is now felt to be caused by antiacetylcholine receptor antibodies, which block uptake of the neural impulse at the neuromuscular junction, one can speculate that penicillamine may induce antibody to acetylcholine receptors and thereby cause myasthenia in susceptible patients. So far, more than 30 cases of penicillamine-induced myasthenia have been reported, and almost all of the cases have resolved simply by withdrawing the drug. . . . Treatment with standard antimyasthenia therapy is usually unnecessary.

—PAUL E. PATAKY, MD, Boston

Extracted from *Audio-Digest Ophthalmology*, Vol. 17, No. 20, in the Audio-Digest Foundation's subscription series of tape-recorded programs. For subscription information: 1577 East Chevy Chase Drive, Glendale, CA 91206.